Creatv Bio

Executive Summary

Creatv Bio is a US-based biotechnology company established in 2010, specializing in innovative cancer diagnostics. The company's proprietary microfluidic platform detects and analyzes circulating rare cells in blood, specifically Cancer Associated Macrophage-Like Cells (CAMLs) and Circulating Tumor Cells (CTCs). This liquid biopsy approach enables early detection, monitoring, and treatment guidance across multiple cancer types, addressing a significant unmet need in oncology. Creatv's technology offers a non-invasive method to capture real-time tumor dynamics, potentially improving patient outcomes and reducing healthcare costs. The company is privately held and operates from Potomac, Maryland, with a focus on advancing its diagnostic platforms toward clinical adoption. Creatv Bio's technology has the potential to revolutionize cancer management by providing more accurate and accessible diagnostics compared to traditional tissue biopsies. The company's CAML-based platform, in particular, targets a unique biomarker that correlates with metastatic progression and therapy response. With the liquid biopsy market projected to grow rapidly, Creatv Bio is well-positioned to capture market share if it achieves regulatory clearances and clinical validation. However, the company faces competition from established players and must navigate the rigorous FDA approval process. Near-term catalysts include FDA clearance for its lead diagnostic test and publication of pivotal clinical data. Successful execution could lead to strategic partnerships or acquisition interest from larger diagnostics firms.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance for CAML-based liquid biopsy test50% success
• Q3 2026Publication of pivotal clinical study results in a peer-reviewed journal70% success
• Q2 2027Strategic partnership or co-development agreement with a major pharmaceutical company30% success